Press "Enter" to skip to content

Bayer’s Stivarga® (regorafenib) becomes first compound used in clinical trial platform to investigate new therapies for brain cancer – BioSpace

admin 0

Bayer’s Stivarga® (regorafenib) becomes first compound used in clinical trial platform to investigate new therapies for brain cancer  BioSpace

WHIPPANY, N.J., June 19, 2019 /PRNewswire/ — Bayer announced today that the Stivarga® (regorafenib) arm of the platform trial GBM AGILE (Glioblastoma …

“liver cancer” – Google News

(Visited 3 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *